Published Application/Species/Sample/Dilution | Reference |
---|
- flow cytometry; human; loading ...; fig 6a
| Cherkassky L, Morello A, Villena Vargas J, Feng Y, Dimitrov D, Jones D, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130-44 pubmed publisher
|
| Lu S, De Neef E, Thomas J, SABIO E, Rousseau B, Gigoux M, et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021;184:4032-4047.e31 pubmed publisher
|
| Wagle M, Vervoort S, Kelly M, Van Der Byl W, Peters T, Martin B, et al. Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance. Nat Commun. 2021;12:2782 pubmed publisher
|
| Mitchell J, Lund M, Starmer J, Ge K, Magnuson T, Shpargel K, et al. UTX promotes CD8+ T cell-mediated antiviral defenses but reduces T cell durability. Cell Rep. 2021;35:108966 pubmed publisher
|
| Lv Z, Zhang P, Li D, Qin M, Nie L, Wang X, et al. CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. Oncoimmunology. 2020;9:1747688 pubmed publisher
|
| Rudd C, Chanthong K, Taylor A. Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity. Cell Rep. 2020;30:2075-2082.e4 pubmed publisher
|
| Dong M, Wang G, Chow R, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019;178:1189-1204.e23 pubmed publisher
|
| Yang B, Wang K, Wan S, Liang Y, Yuan X, Dong Y, et al. TCF1 and LEF1 Control Treg Competitive Survival and Tfr Development to Prevent Autoimmune Diseases. Cell Rep. 2019;27:3629-3645.e6 pubmed publisher
|
| Hu Q, Sun W, Wang J, Ruan H, Zhang X, Ye Y, et al. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. Nat Biomed Eng. 2018;2:831-840 pubmed publisher
|
| Lu Y, Wang Q, Xue G, Bi E, Ma X, Wang A, et al. Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell. 2018;33:1048-1060.e7 pubmed publisher
|
| de Souza A, Rudin S, Chang R, Mitchell K, Crandall T, Huang S, et al. ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2?×?Ob1)F1 Mice by Induction of IL-10-Secreting iTregs. Neurol Ther. 2018;7:103-128 pubmed publisher
|
| Smith L, Boukhaled G, Condotta S, Mazouz S, Guthmiller J, Vijay R, et al. Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. Immunity. 2018;48:299-312.e5 pubmed publisher
|
| Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8:2256 pubmed publisher
|
| Fortner K, Bond J, Austin J, Boss J, Budd R. The molecular signature of murine T cell homeostatic proliferation reveals both inflammatory and immune inhibition patterns. J Autoimmun. 2017;82:47-61 pubmed publisher
|
| Huang R, Francois A, McGray A, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 pubmed publisher
|
| Clement M, Marsden M, Stacey M, Abdul Karim J, Gimeno Brias S, Costa Bento D, et al. Cytomegalovirus-Specific IL-10-Producing CD4+ T Cells Are Governed by Type-I IFN-Induced IL-27 and Promote Virus Persistence. PLoS Pathog. 2016;12:e1006050 pubmed publisher
|